Immunology

- Achieves 92% Accuracy in AI Cytotoxicity Algorithm, Maximizing Efficiency in Drug Development

- Shaperon Strengthens Academic Collaboration for AI Algorithm Development Specializing in Inflammatory Diseases

[Cambridge, Massachusetts / Research Triangle Park, North Carolina / Seoul, Korea | July 2, 2024] Hudson Therapeutics announced that Shaperon, Inc. (Kosdaq 378800, CEO Seung-Yong Seong), a biotech company specializing in innovative immune therapeutics and a headquarter of Hudson in Korea, has achieved a significant milestone with its AI-driven drug development platform, AIDEN. AIDEN’s proprietary AI algorithms now boast a 92% accuracy rate in cytotoxicity algorithm, enhancing the efficiency of drug development processes.  

AIDEN functions as an advanced AI platform leveraging deep learning technologies, analyzing over 240 million data points including low molecular weight compounds, protein structures, and biological activity data collected over the past year. 

This achievement follows rigorous refinement of AI training data focused on optimizing drug candidate screening, thereby maximizing data efficiency. The improved accuracy in the cytotoxicity algorithm allows for effective screening of candidate materials, enhancing reliability in predicting biological activity and potential toxicity. This advancement is expected to significantly reduce the time and cost associated with drug candidate exploration, traditionally spanning 4-5 years.

Dr. Seung-Yong Seong, CEO of Shaperon, commented, "Achieving 92% accuracy in AIDEN's cytotoxicity algorithm marks a substantial improvement from previous AI algorithms, typically ranging from 70-80%. By further advancing AI algorithms, including drug absorption studies, we aim to expedite the discovery of new candidate materials."

In a strategic move to bolster its expertise in inflammatory diseases, Shaperon recently entered into a collaboration with Professor Rajendra Karkee of Seoul National University. This partnership aims to advance AI algorithms specialized in inflammasomes, crucial for developing optimized treatments targeting inflammatory conditions. Professor Karkee, a global authority in innate immunity and inflammasome research, brings invaluable insights to the collaboration.

Looking ahead, Shaperon plans to strengthen its proprietary AI platform through proactive collaborations with external partners, leveraging acquired research outcomes to drive innovations in drug development.